You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Humanized Monoclonal Antibody to Treat Acinetobacter Infections

    SBC: BIOLOGICAL ANTI-INFECTIVE MEDICINES, LLC            Topic: NIAID

    DESCRIPTIONprovided by applicantNational surveillance data confirm thatof Abaumannii isolates from US intensive care units are extreme drug resistanceXDRfar higher than other pathogensAt leastandcases of XDR Abaumannii infections occur annually in the US and globallyin developed countriesrespectivelyThese infections result inanddeaths and excess healthcare costs of $million and $million in the US ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Development and Preclinical Testing of the TORVAD Ventricular Assist System in Preparation for First in Human Implantation

    SBC: WINDMILL CARDIOVASCULAR            Topic: NHLBI

    DESCRIPTIONprovided by applicantThe TORVAD tmis a unique ventricular assist system that delivers low shearsynchronouspulsatile flowBlood shear due to pumping is minimized by the relatively low speed of pistons supported by hydrodynamic bearings designed to maintain a fixed gap between the piston and torus wallsThe TORVAD synchronizes with the heart to preserve aortic valve flow and maintains autor ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Development and Preclinical Testing of the TORVAD Ventricular Assist System in Preparation for First in Human Implantation

    SBC: WINDMILL CARDIOVASCULAR            Topic: NHLBI

    DESCRIPTIONprovided by applicantThe TORVAD tmis a unique ventricular assist system that delivers low shearsynchronouspulsatile flowBlood shear due to pumping is minimized by the relatively low speed of pistons supported by hydrodynamic bearings designed to maintain a fixed gap between the piston and torus wallsThe TORVAD synchronizes with the heart to preserve aortic valve flow and maintains autor ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  4. TP508: A New Drug for Mitigating Lethals Effects of Radiation Exposure

    SBC: Chrysalis BioTherapeutics, Inc.            Topic: NIAID

    DESCRIPTIONprovided by applicantWith increasing risk of a nuclear accident or detonationthere is a critical need to develop effective medicinal countermeasures that can be delivered to victims after an incident to increase survival and prevent long term effects in those that surviveMajor causes of death following a nuclear incident include acute radiation syndromesARSthat destroy hematopoietic ste ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  5. A glycolipid adjuvant to promote dose sparing, accelerate immunization schedules and extend durability of high-level protection with a live attenuated sporozoite malaria vaccine

    SBC: SANARIA INC.            Topic: R

    DESCRIPTIONprovided by applicantThe world needs a highly effective malaria vaccineSanaria rPfSPZ Vaccinecomposed of asepticpurifiedcryopreserved radiation attenuated PfSPZprotectedof volunteers in an NIH clinical trialThe vaccine has been administered by direct venous inoculationDVItosubjects in MaliTanzaniaEquatorial GuineaEGand USASafetytolerabilityhigh grade protectionheterologous protection af ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Phase IIa study of VBP for Duchenne muscular dystrophy

    SBC: REVERAGEN BIOPHARMA, INC.            Topic: 106

    DESCRIPTION provided by applicant ReveraGen BioPharma is a clinical stage drug development company that is developing VBP a novel dissociative steroidal class drug The initial indication for development is Duchenne muscular dystrophy where VBP holds promise for retaining or increasing efficacy of glucocorticoids while reducing side effects bone fragilit stunting of growth VBP is c ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Regulatory Approval & Commercialization of an RBC Processing and Storage System to Improve Transfusion Therapy by Minimizing Oxidative Damage to RBC during Storage

    SBC: NEW HEALTH SCIENCES, INC.            Topic: NHLBI

    DESCRIPTIONprovided by applicantThe objective of this project is to commercialize the Hemanext Storage System to deliver red blood cellsRBCof significantly improved quality by establishing and maintaining an anaerobic environment for refrigerated RBC storageThe higher quality red blood cell product will exhibit bioequivalence vsconventionally prepared RBC with lower doses by virtue of higher RBC r ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  8. PfSPZ Vaccines: Quality Systems, Manufacturing, Regulatory, and Clinical Quality and Data Management Support for Product Commercialization

    SBC: SANARIA INC.            Topic: NIAID

    ABSTRACT Sanaria s Plasmodium falciparumPfsporozoiteSPZvaccines development program is receiving overwhelming global supportEleven trials of Sanaria s two primary PfSPZ vaccines which includesubjectswere initiated in lateTanzaniaU Sor will start in earlyKenyaGhanaEquatorial GuineaEGBurkina FasoGermanyand the U SThese trials will assesstodose regimens based on a trial in Germany showingprotective e ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Universal Attenuated Sporozoite Vaccine and Challenge System

    SBC: SANARIA INC.            Topic: NIAID

    ABSTRACT Sanaria s Plasmodium falciparumPfsporozoiteSPZvaccines development program is receiving global supportTrials of PfSPZ Vaccineradiation attenuated PfSPZor PfSPZ CVacPfSPZ Chemoprophylaxis Vaccineadministered by direct venous inoculationDVIincludingadults to infants were initiated in DecemberTanzaniaU Sor will be initiated in earlyin MaliKenyainfantsGhanaEquatorial GuineaGermany andaddition ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Development of a Biochemical Diagnosis for Creutzfeldt Jakob disease

    SBC: Amprion, Inc.            Topic: 101

    ABSTRACT Human prion diseases are infectious and invariably fatal neurodegenerative diseases including sporadic Creutzfeldt Jakob disease sCJD the most common form and variant CJD vCJD which is associated to consumption of cattle meat infected by bovine spongiform encephalopathy Currently there is not sensitive objective and non invasive biochemical diagnosis for these diseases and even ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government